Diversify Wealth Management LLC Increases Stake in Prestige Consumer Healthcare Inc. $PBH

Diversify Wealth Management LLC increased its position in Prestige Consumer Healthcare Inc. (NYSE:PBH) by 88.9% in the first quarter, HoldingsChannel.com reports. The fund owned 31,566 shares of the company’s stock after buying an additional 14,857 shares during the period. Diversify Wealth Management LLC’s holdings in Prestige Consumer Healthcare were worth $1,768,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also made changes to their positions in PBH. AQR Capital Management LLC boosted its stake in shares of Prestige Consumer Healthcare by 11.9% in the first quarter. AQR Capital Management LLC now owns 30,056 shares of the company’s stock worth $2,558,000 after buying an additional 3,200 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of Prestige Consumer Healthcare by 4.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 29,490 shares of the company’s stock worth $2,535,000 after buying an additional 1,289 shares during the period. Goldman Sachs Group Inc. raised its stake in shares of Prestige Consumer Healthcare by 28.4% during the 1st quarter. Goldman Sachs Group Inc. now owns 546,672 shares of the company’s stock worth $46,997,000 after buying an additional 120,965 shares during the period. Jane Street Group LLC lifted its position in shares of Prestige Consumer Healthcare by 204.0% during the 1st quarter. Jane Street Group LLC now owns 104,802 shares of the company’s stock valued at $9,010,000 after buying an additional 70,330 shares in the last quarter. Finally, Geneos Wealth Management Inc. lifted its position in shares of Prestige Consumer Healthcare by 92.8% during the 1st quarter. Geneos Wealth Management Inc. now owns 559 shares of the company’s stock valued at $48,000 after buying an additional 269 shares in the last quarter. 99.95% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several brokerages recently commented on PBH. Oppenheimer lowered shares of Prestige Consumer Healthcare from an “outperform” rating to a “market perform” rating in a report on Thursday, May 14th. Canaccord Genuity Group decreased their price objective on shares of Prestige Consumer Healthcare from $86.00 to $72.00 and set a “buy” rating on the stock in a report on Friday, May 15th. Weiss Ratings lowered shares of Prestige Consumer Healthcare from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Thursday, June 25th. Finally, Zacks Research lowered shares of Prestige Consumer Healthcare from a “hold” rating to a “strong sell” rating in a research report on Monday, May 18th. Two investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, Prestige Consumer Healthcare has an average rating of “Hold” and a consensus price target of $70.75.

Prestige Consumer Healthcare Price Performance

Shares of Prestige Consumer Healthcare stock opened at $47.17 on Wednesday. The stock has a market capitalization of $2.23 billion, a P/E ratio of 12.06, a PEG ratio of 1.57 and a beta of 0.35. The business has a 50 day simple moving average of $48.15 and a two-hundred day simple moving average of $57.59. Prestige Consumer Healthcare Inc. has a 12 month low of $42.62 and a 12 month high of $77.45. The company has a debt-to-equity ratio of 0.54, a current ratio of 3.57 and a quick ratio of 2.25.

Prestige Consumer Healthcare (NYSE:PBH) last issued its quarterly earnings results on Wednesday, May 13th. The company reported $1.23 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.39 by ($0.16). Prestige Consumer Healthcare had a return on equity of 11.54% and a net margin of 17.48%.The firm had revenue of $281.62 million during the quarter, compared to analyst estimates of $293.64 million. During the same period in the prior year, the firm earned $1.32 earnings per share. The business’s revenue was down 5.0% on a year-over-year basis. Prestige Consumer Healthcare has set its FY 2027 guidance at 4.420-4.510 EPS. As a group, analysts predict that Prestige Consumer Healthcare Inc. will post 4.45 EPS for the current fiscal year.

Insiders Place Their Bets

In other Prestige Consumer Healthcare news, VP Jeffrey Zerillo sold 1,207 shares of the firm’s stock in a transaction on Tuesday, May 5th. The stock was sold at an average price of $54.99, for a total value of $66,372.93. Following the transaction, the vice president owned 42,820 shares in the company, valued at approximately $2,354,671.80. This trade represents a 2.74% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 1.50% of the company’s stock.

Prestige Consumer Healthcare Profile

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).